Abdera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13

Audio By Carbonatix

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 18, 2025--

Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for cancer, today announced that Lori Lyons-Williams, president and chief executive officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:00 a.m. PT.

Ms. Lyons will provide an overview of the company and its pipeline of first-in-class radiotherapeutics, including ABD-147 targeting delta-like ligand 3 (DLL3) that is currently being evaluated in a Phase 1 clinical trial for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), and ABD-320, targeting 5T4 with pan-cancer potential, which is on-track to enter clinical development in 2026.

About Abdera

Abdera Therapeutics is a clinical-stage biopharmaceutical company leveraging antibody engineering to design and develop new precision radiopharmaceuticals for cancer. Abdera’s R adio O ptimized V ector E nginee r ing (ROVEr™) proprietary platform enables the company to engineer potential best-in-class therapies for both clinically validated and novel targets that deliver potent radioisotopes capable of emitting alpha or beta particles to selectively destroy cancer cells. Abdera’s lead program, ABD-147, is a precision radiopharmaceutical biologic therapy designed to deliver Actinium-225 ( 225 Ac) to solid tumors expressing delta-like ligand 3 (DLL3) for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). To learn more, please visit www.abderatx.com and follow us on LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251217640412/en/

CONTACT: Investors:

Monique Allaire

THRUST

[email protected]:

1AB

Katie Engleman

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH OTHER HEALTH GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Abdera Therapeutics Inc.

Copyright Business Wire 2025.

PUB: 12/18/2025 08:00 AM/DISC: 12/18/2025 08:02 AM

http://www.businesswire.com/news/home/20251217640412/en